Amicus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Amicus Therapeutics

10/05/2023 14:31

* Amicus Therapeutics Inc  FOLD.OQ  reported a quarterly
adjusted
loss of 18 cents​​ per share for the quarter ended in March. The
mean expectation of twelve analysts for the quarter was for a
loss of 15 cents per share.
    * Revenue rose 9.6% to $86.27 million from a year ago;
analysts
expected $83.08 million. 
    * Amicus Therapeutics Inc's reported EPS for the quarter was
a
loss of 18 cents​.
    * The mean earnings estimate of analysts had fallen by
about 25.7%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates 
    * Amicus Therapeutics Inc shares had risen by 9.9% this
quarter and lost 0.2% so far this year.
    * The company reported a quarterly loss of $52.93 million.
    * Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.15          -0.18          Missed
 Dec. 31 2022      -0.13          -0.19          Missed
 Sep. 30 2022      -0.19          -0.12          Beat
 Jun. 30 2022      -0.22          -0.21          Beat